COMPANY

Santen

FDA-cleared device company Clinical Phase 3

Keywords: ophthalmology Glaucoma and Ocular Hypertension Ocular Hypertension Age-Related Macular Degeneration Open-angle Glaucoma Dry Eye Diabetic Macular Edema Primary Open Angle Glaucoma Dry Eye Syndromes Open-Angle Glaucoma or Ocular Hypertension Ocular Surface Disease Primary Open-angle Glaucoma and Ocular Hypertension Glaucoma Choroidal Neovascularization Fuchs Endothelial Corneal Dystrophy Myopia Acquired Blepharophimosis Dry Eye Disease With Severe Keratitis Presbyopia Keratitis Non Infectious Uveitis Vernal Keratoconjunctivitis Vernal Conjunctivitis Dry Eye Disease Diabetic Retinopathy Moderate to Severe Dry Eye Syndrome DE-117 DE-112 DE-101 DE-120 NOVA22007 ''Cyclosporine'' MS-R001 (rapamycin) DE-130A

Profile checked Oct 10, 2026

54Trials (company is sponsor)

Timeline

Mar 19, 2026 Trial start —: PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group source ↗
Jul 29, 2025 Trial start —: Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life. source ↗
Dec 30, 2024 Trial start 3: LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. source ↗
Dec 22, 2022 Trial start Phase 2: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia source ↗
May 19, 2022 Trial start Phase 2: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) source ↗
Sep 30, 2021 Trial start Not phased (device or behavioral study): 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis source ↗
May 11, 2021 Trial start Not phased (device or behavioral study): 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis source ↗
Dec 17, 2020 Trial start Phase 2: Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or source ↗
May 31, 2019 Trial start Phase 3: 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) source ↗
Apr 10, 2019 Trial start III: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocu source ↗
Jan 28, 2019 Trial start Phase 2: Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 source ↗
Nov 19, 2018 Trial start III: LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the source ↗
Sep 27, 2018 Trial start Phase 3: DE-117 Spectrum 5 Study source ↗
Sep 27, 2018 Trial start III: A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectru source ↗
Sep 14, 2018 Trial start III: A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectru source ↗
Jul 25, 2017 Trial start II: A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study source ↗
Jul 5, 2017 Trial start Phase 2: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects source ↗
Mar 28, 2017 Trial start Phase 4: Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis source ↗
Sep 16, 2015 Trial start I: A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration source ↗
2015-04 Trial start Phase 2: A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration source ↗
Sep 29, 2014 Trial start III: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posteri source ↗
2014-06 Trial start II: Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension source ↗
2014-06 Trial start Phase 1: A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension source ↗
2014-01 Trial start I: A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration source ↗
2013-05 Trial start Phase 2: Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension source ↗

Showing 25 of 50 dated events.

Upcoming milestones

2027-09 (ESTIMATED) · · PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group · NCT07235592

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 54

Record	Title	Phase	Status	Start	Primary completion
NCT05376176	A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)	Phase 2	Completed	May 19, 2022	May 26, 2025 (actual)
NCT07235592	PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group	Not listed	Recruiting	Mar 19, 2026	2027-09 (estimated)
NCT06912802	Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.	Not listed	Completed	Jul 29, 2025	Apr 17, 2026 (actual)
NCT06514612	LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.	3	Recruiting	Dec 30, 2024	Aug 1, 2026 (estimated)
NCT04685109	3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis	Not phased (device or behavioral study)	Active, not recruiting	May 11, 2021	Sep 30, 2026 (estimated)
NCT04701086	3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis	Not phased (device or behavioral study)	Completed	Sep 30, 2021	Apr 28, 2025 (actual)
NCT04144413	3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)	Phase 3	Completed	May 31, 2019	Jul 14, 2023 (actual)
NCT05665387	Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia	Phase 2	Completed	Dec 22, 2022	Jul 27, 2023 (actual)
NCT04133311	A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension	III	Completed	Apr 10, 2019	Feb 3, 2022 (actual)
NCT03237936	Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis	Phase 4	Completed	Mar 28, 2017	Jul 11, 2018 (actual)
NCT03711929	LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye	III	Terminated	Nov 19, 2018	Jun 14, 2022 (actual)
NCT03697811	DE-117 Spectrum 5 Study	Phase 3	Completed	Sep 27, 2018	Jan 13, 2022 (actual)
NCT03691649	A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study	III	Completed	Sep 14, 2018	Dec 6, 2019 (actual)
NCT03691662	A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study	III	Completed	Sep 27, 2018	Oct 23, 2019 (actual)
NCT04742283	Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension	Phase 2	Completed	Dec 17, 2020	Dec 7, 2021 (actual)
NCT01751126	Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis	Phase 3	Completed	Apr 29, 2013	2016-02 (actual)
NCT00328653	Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)	Phase 2/Phase 3	Completed	2006-05	Feb 22, 2007 (actual)
NCT03211234	Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects	Phase 2	Completed	Jul 5, 2017	Dec 31, 2019 (actual)
NCT03216902	A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study	II	Completed	Jul 25, 2017	Feb 27, 2018 (actual)
NCT03858894	Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6	Phase 2	Completed	Jan 28, 2019	Jun 20, 2019 (actual)
NCT02251938	A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program	III	Completed	Sep 29, 2014	Nov 1, 2017 (actual)
NCT02555306	A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration	I	Completed	Sep 16, 2015	2017-08 (actual)
NCT01358266	Study Assessing Double-masked Uveitis Treatment	Phase 3	Completed	2011-05	2016-09 (actual)
NCT01654484	A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT	Phase 1/Phase 2	Completed	2012-07	2012-11 (actual)
NCT02022501	A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration	I	Completed	2014-01	Apr 21, 2016 (actual)
NCT02401945	A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration	Phase 2	Completed	2015-04	Jun 22, 2016 (actual)
NCT01868126	Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension	Phase 2	Completed	2013-05	2013-08 (actual)
NCT02179008	Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension	II	Completed	2014-06	2015-01 (actual)
NCT02102750	A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension	Phase 1	Completed	2014-06	May 29, 2017 (actual)
NCT01254370	Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease	Phase 2	Completed	2010-11	2011-06 (actual)
NCT00739349	NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye	Phase 2	Completed	2008-08	2009-01 (actual)
NCT00665106	Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy	Phase 1	Completed	2008-04	2011-09 (actual)
NCT01239069	Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease	Phase 2	Completed	2010-11	2011-10 (actual)
NCT01087671	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops	Phase 3	Completed	2010-04	2010-10 (actual)
NCT01292460	Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies	Phase 3	Completed	2011-02	2012-09 (actual)
NCT00814944	A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model	Phase 2	Completed	2009-04	2009-10 (actual)
NCT00766337	Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration	2	Terminated	2008-12	2009-11 (actual)
NCT00712491	Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration	1	Terminated	2008-09	2009-11 (actual)
NCT00656643	Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema	Phase 2	Completed	2008-06	2009-11 (actual)
NCT01279083	Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension	Phase 1/Phase 2	Completed	2011-01	2011-11 (actual)
NCT01468168	A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients	Phase 2	Completed	2011-10	2012-11 (actual)
NCT01306461	Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations	Phase 3	Completed	2011-03	2012-04 (actual)
NCT01434888	Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops	Phase 1	Completed	2011-09	2011-12 (actual)
NCT00868894	Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension	Phase 1/Phase 2	Completed	2009-03	2010-05 (actual)
NCT00650338	Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension	Phase 2	Completed	2008-03	2008-09 (actual)
NCT01118754	Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients	Phase 1/Phase 2	Completed	2010-04	2010-12 (actual)
NCT00918346	Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation	Phase 3	Completed	2005-09	2006-03 (actual)
NCT00401115	Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy	Phase 1	Completed	2006-09	2008-06 (actual)
NCT00814515	Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome	Phase 3	Completed	2007-09	2009-09 (actual)
NCT00879099	Interaction Study of Timolol Eye Drops and Paroxetine Capsules	Phase 1	Completed	2009-04	2010-01 (actual)